D. Boral Capital Reaffirms “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

D. Boral Capital restated their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a report released on Thursday morning,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Several other research analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $43.70.

UroGen Pharma Stock Performance

NASDAQ:URGN opened at $10.15 on Thursday. The stock’s 50 day moving average price is $11.25 and its two-hundred day moving average price is $13.01. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million for the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the prior year, the firm earned ($0.68) EPS. On average, equities research analysts predict that UroGen Pharma will post -3.1 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of URGN. SG Americas Securities LLC lifted its position in shares of UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock worth $216,000 after purchasing an additional 6,207 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock valued at $864,000 after buying an additional 49,318 shares during the last quarter. Tidal Investments LLC increased its holdings in UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock worth $477,000 after purchasing an additional 6,030 shares in the last quarter. Barclays PLC raised its stake in shares of UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after purchasing an additional 48,040 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of UroGen Pharma by 8.1% during the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after buying an additional 34,248 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.